Diroximel fumarate - Open Access .click

Results 31 to 40 of about 164 (107)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate

Cureus, 2023
Multiple sclerosis (MS) is an autoimmune demyelinating disorder that disproportionately affects middle-aged women, and is capable of resulting in severe disability. However, the use of disease-modifying therapies has profoundly contributed to the improvement in the morbidity of the disorder. Diroximel fumarate (DRF) is a second-generation drug that has
Gül, Sedat, Ahmed, Adeenah F, McGraw, Corey +2 more
openaire +2 more sources

MSJ881761_supplementary_appendix – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2019
Supplemental material, MSJ881761_supplementary_appendix for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S Wolinsky ...
Mark S Freedman (5235176) +19 more
core +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1565-1573, June 2026.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh +4 more
wiley +1 more source

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies [PDF]

, 2021
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course.
Naylor, Maria L +13 more
core +1 more source

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau +62 more
wiley +1 more source

MSJ-19-0334.R2_Supplemental_Figure_2 – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2019
Supplemental material, MSJ-19-0334.R2_Supplemental_Figure_2 for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S ...
Mark S Freedman (5235176) +19 more
core +1 more source

Diagnoses of Multiple Sclerosis and Related Disorders and Disease‐Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health Registries

Brain and Behavior, Volume 16, Issue 2, February 2026.
This study aimed to describe and compare information on diagnoses of MS and related disorders as well as treatments with disease‐modifying therapies (DMTs) available in three national registries, highlighting the key differences relevant to MS research.
Hanna Joensen +3 more
wiley +1 more source

MSJ-19-0334.R2_Supplemental_Figure_1 – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2019
Supplemental material, MSJ-19-0334.R2_Supplemental_Figure_1 for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S ...
Mark S Freedman (5235176) +19 more
core +1 more source

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Annals of Clinical and Translational Neurology, Volume 12, Issue 11, Page 2214-2225, November 2025.
ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler +43 more
wiley +1 more source

Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease‐Modifying Treatments for Multiple Sclerosis

European Journal of Neurology, Volume 32, Issue 11, November 2025.
ABSTRACT Background Regenerative strategies in progressive multiple sclerosis (MS) pose a significant unmet need. Combining immunomodulatory treatment with remyelinating interventions to target the complex underlying pathogenesis appeals as the next frontier in MS therapeutic developments.
Anna‐Victoria De Keersmaecker +11 more
wiley +1 more source

multiple sclerosis
dimethyl fumarate
neurology

diseases of the nervous system
adherence